Tech Company Financing Transactions
Neurenati Therapeutics Funding Round
Neurenati Therapeutics closed a $1.2 million Seed financing round on 2/29/2024. Investors included Genson Capital and private investors.
Transaction Overview
Company Name
Announced On
2/29/2024
Transaction Type
Venture Equity
Amount
$1,200,000
Round
Seed
Investors
Genson Capital (Lead Investor)
Proceeds Purpose
The company intends to use the funds to accelerate the development of NEU-001, a therapy to Hirschsprung's disease (HSCR), a rare gastrointestinal condition affecting approximately 100 Canadian newborns every year.
Company Information
Company Status
Private & Independent
Industry
Healthcare Services
Mailing Address
630 René-Lévesque Blvd W. 20th floor
Montreal, Quebec, H3B 1S6
Canada
Montreal, Quebec, H3B 1S6
Canada
Phone
Website
Email Address
Overview
Based in Montreal, Neurenati Therapeutics is a pioneering biotechnology company developing an innovative treatment for Hirschsprung disease. Nicolas Pilon, an expert in rare diseases, and Rodolphe Soret, a specialist in neuro-gastroenterology, have combined their expertise to develop an innovative treatment for Hirschsprung disease.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Maxime Ranger
Chief Scientific Officer
Nicolas Pilon
Co-Founder
Rodolphe Soret
Browse more venture capital transactions:
Prev: 2/29/2024: Valisure venture capital transaction
Next: 2/29/2024: Reset Financial Technologies venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on all VC transactions involving tech companies. All VC database entries reported here come from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs